SSE terminates BrightGene Bio-Medical's specific share issuance review

BrightGene Bio-Medical Technology (Suzhou) Co., Ltd. announced that the Shanghai Stock Exchange (SSE) has terminated its review of the company's proposed share issuance to specific targets. This decision was conveyed in the "Decision on terminating the review of the issuance of shares to specific targets by BrightGene Bio-Medical Technology (Suzhou) Co., Ltd." received on October 17, 2025.

The termination follows the company's decision on October 15, 2025, to withdraw its application for the 2024 annual specific target A-share issuance. This withdrawal was approved during the fourth board meeting, thirteenth session, and publicly announced on October 16, 2025.

Consequently, BrightGene Bio-Medical Technology and its sponsor, Sinolink Securities Underwriting & Sponsoring Co., Ltd., submitted applications to the SSE to formally withdraw both the share issuance application and the sponsorship work. The SSE's decision to terminate the review is in accordance with relevant regulations, including Article 19 and Article 63 of the "Shanghai Stock Exchange Rules for Review of Listing of Companies Issuing Securities."